Medications

AstraZeneca reorg to cut 1,600 jobs in US, UK

(AP)—Struggling Anglo-Swedish drugmaker AstraZeneca PLC said Monday that it will eliminate 1,600 jobs, mostly in the U.S. and United Kingdom, as its new CEO starts a major research and development reorganization.

Other

$580 million EU antitrust fine for drug makers

The European Union's antitrust body is imposing a fine of 428 million euros ($580 million) on France's pharmaceutical company Servier and five producers of generic medicines for distorting competition.

Other

Novartis Q4 net profit rises to $2.0 billion

Swiss drug maker Novartis AG reported a 2 percent rise in fourth-quarter net profit Wednesday, helped by delays in generic competition to its blockbuster drugs.

Other

Future pandemics targeted by new Oxford research center

Oxford University is launching an effort to bring together academic, industry and government experts from around the world to use the lessons learned from COVID-19 in the fight against future pandemics.

Health

Competition keeps health-care costs low, researchers find

Medical practices in less competitive health-care markets charge more for services, according to a study conducted by researchers at the Stanford University School of Medicine and the National Bureau of Economic Research.

Other

Pfizer 3Q net falls due to generics, higher costs

Pfizer Inc.'s third-quarter profit dropped 19 percent as competition from generic drugs continued to cut sales, while lower operating expenses failed to offset higher taxes and charges.

Other

AstraZeneca to pay about $260M for Omthera Pharma (Update 2)

British drugmaker AstraZeneca PLC plans to spend about $260 million on Omthera Pharmaceuticals Inc., a specialty drug developer with only 14 employees but has a potential treatment for patients who have high levels of fats ...

page 14 from 17